H19 is a maternally expressed noncoding RNA located at chromosome 11p15.5 near the reciprocally imprinted insulin-like growth factor 2 (IGF2) gene. Though the function of H19 is unknown, it is transcribed during embryonic development after which transcription is absent in all but a few tissues including cardiac muscle, breast, ovary, uterus, and placenta. Over the past fifteen years, however, high H19 expression has been seen in a number of human cancers. Recently, the 2.6kb H19 transcript was shown to be the premiRNA of miR-675 whose target mRNA is the tumor suppressor RB1.
We have carried out real-time PCR assays for H19, miR-675, and RB1 transcription in seven endometrial cancer cell lines and a panel of 27 primary endometrial tumors. Results showed that H19 and miR-675 expression is highly correlated (r = 0.84) and that miR-675 and RB1 expression levels are negatively correlated (r = -0.52). Among the primary tumors, miR-675 expression is unchanged in endometrioid tumors compared to benign endometrium (-1.3 fold) but is increased in carcinosarcomas (2.7 fold) and is highest in serous tumors (7.2 fold).
Linking H19, miR-675 and RB1 expression with serous tumors of the endometrium suggests that RB1 suppression may be a differentiating event in serous tumorigenesis.
